CXCL9 Antibody

Definition and Mechanism

CXCL9 belongs to the CXC chemokine family and is primarily induced by interferon-gamma (IFN-γ). It binds to the CXCR3 receptor, mediating immune cell recruitment (e.g., T cells, NK cells) to sites of inflammation . The antibody targets CXCL9 to enable its detection in biological samples, such as serum, plasma, or tissue sections.

Applications

The CXCL9 Antibody is used across multiple experimental and clinical platforms:

Cancer Immunology

• Tumor Microenvironment (TME): CXCL9 recruits anti-tumor immune cells, such as cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, into tumors. Elevated CXCL9 levels correlate with favorable clinical outcomes in checkpoint inhibitor therapies .

• Therapeutic Targeting: Blocking the CXCL9/CXCR3 axis has shown potential in modulating tumor-associated macrophages (TAMs), shifting their polarization from pro-tumor (M2) to anti-tumor (M1) phenotypes .

Inflammatory Diseases

• Heart Failure: CXCL9, -10, and -11 are validated biomarkers for adverse cardiac remodeling and left ventricular dysfunction .

• COVID-19: High serum CXCL9 levels are observed in acute infections, indicating its role in T1 inflammation .

Autoimmune Disorders

• Hashimoto’s Thyroiditis: Proteomic studies highlight CXCL9 as a potential biomarker for disease progression .

Clinical Relevance

The development of automated immunoassays, such as the Sysmex HISCL system, enables rapid quantification of CXCL9 in clinical settings . This has expanded its utility in:

• Diagnosis: Detecting Q fever and monitoring immune responses in infections .

• Prognosis: Predicting therapeutic outcomes in cancer and inflammatory diseases .